Science Translational Medicine 2018-04-04

Fighting leukemia with “duel”-targeted therapy

Tríona Ní Chonghaile

Index: 10.1126/scitranslmed.aat3887

Full Text: HTML

Abstract

Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients.

Latest Articles:

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

2018-04-11

[10.1126/scitranslmed.aao3003]

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

2018-04-11

[10.1126/scitranslmed.aan3311]

Spooked neutrophils unmask sepsis

2018-04-11

[10.1126/scitranslmed.aat3891]

Adult neurogenesis in humans: Dogma overturned, again and again?

2018-04-11

[10.1126/scitranslmed.aat3893]

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms

2018-04-11

[10.1126/scitranslmed.aan8292]

More Articles...